Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Discover how psoriasis affects immune function and the role of SSAT1 in this chronic skin condition. Learn more now.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

How the Mediterranean diet’s transformative power fights stubborn skin disorders—discover the science-backed strategies ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...